Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seroquel and Lithium for Maintenance Treatment of Bipolar I Disorder
NCT00314184Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of quetiapine in bipolar I disorder (3 arms), sponsored by AstraZeneca. Primary endpoint: Time from randomization to recurrence of a mood event at 104 weeks. Started Mar 2005; status: completed.
02
Drugs
quetiapine
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT00314184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00314184.